INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 430m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
Public company

TLSITriSalus Life Sciences, Inc.

CIK 0001826667

EDGAR filingsOpen in network
Disclosed transactions16
Buys / sells0 / 3
Max Insider Score31
Connections9with evidence

TLSI · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
31
MR
Marshak RichardChief Commercial Officer
TLSITriSalus Life Sciences, Inc.
Open-market sale
SELL$1,427
325 sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 3841 · Surgical & Medical Instruments & Apparatus · Nov 4, 2026
  • ← Insider ofevidence
    Szela Mary TDirector, CEO and President · Oct 7, 2026
  • ← Lobbied forevidence
    CAPITOL HILL CONSULTING GROUPLDA Q1 2026 first quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Insider ofevidence
    Frankenius Equity AB10% Owner · Apr 20, 2026
31
SJ
Stevens JenniferChief Regulatory Officer
TLSITriSalus Life Sciences, Inc.
Open-market sale
SELL
$1,387
316 sh
Oct 5, 2026
Oct 7, 2026
traded Oct 5, 2026
+2d
SEC FORM 4

Evidence

31
CF
Cox Bryan F.Chief of Research
TLSITriSalus Life Sciences, Inc.
Open-market sale
SELL$1,299
296 sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

9
ST
Szela Mary TDirector, CEO and President
TLSITriSalus Life Sciences, Inc.
Tax withholding
F$12K
2,693 sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

24
FA
Frankenius Equity AB10% Owner
TLSITriSalus Life Sciences, Inc.
Derivative conversion
C—
230.0K sh
Jul 31, 2025Apr 20, 2026
traded Jul 31, 2025
+263dSEC FORM 4

Evidence

28
FA
Frankenius Equity AB10% Owner
TLSITriSalus Life Sciences, Inc.
Derivative conversion
C—
759.0K sh
Jul 31, 2025Apr 20, 2026
traded Jul 31, 2025
+263dSEC FORM 4

Evidence

17
SJ
Stevens JenniferChief Regulatory Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
100.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
CF
Cox Bryan F.Chief of Research
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
40.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
CF
Cox Bryan F.Chief of Research
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
80.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
PD
Patience DavidChief Financial Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
65.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
PD
Patience DavidChief Financial Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
130.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
MR
Marshak RichardChief Commercial Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
120.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

21
MR
Marshak RichardChief Commercial Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
60.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

17
DJ
Devlin JodiChief of Clinical Operations
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
100.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

21
DJ
Devlin JodiChief of Clinical Operations
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
50.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

21
SJ
Stevens JenniferChief Regulatory Officer
TLSITriSalus Life Sciences, Inc.
Grant or award
A—
50.0K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Stevens JenniferChief Regulatory Officer · Nov 25, 2025
  • ← Insider ofevidence
    Cox Bryan F.Chief of Research · Nov 25, 2025
  • ← Insider ofevidence
    Patience DavidChief Financial Officer · Nov 25, 2025
  • ← Insider ofevidence
    Devlin JodiChief of Clinical Operations · Nov 25, 2025
  • ← Insider ofevidence
    Marshak RichardChief Commercial Officer · Nov 25, 2025

    • Lobbying

    $180K reported · de-duplicated
    2026 Q2 $90K via firms2026 Q1 $90K via firms
    • CAPITOL HILL CONSULTING GROUP$90K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • CAPITOL HILL CONSULTING GROUP$90K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.